Post-Thrombolysis Hospital Care: Evidence-Based Updates

Care following intravenous thrombolysis (IVT) is critical to ensure safety, monitor for complications, and begin secondary prevention. Recent trials have reshaped traditional practices. Below is an overview of updated standards, supported by modern evidence.

🔹 Bottom Line: Post-Thrombolysis Care

  • Blood Pressure: Target <180 mmHg remains standard.
  • Early Mobilization: AVERT cautioned against <24h mobilization. Mobilization at 12–24h appears safe, but offers no long-term functional gain.
  • Antiplatelets: Hold for 24h post-tPA. CLEAR showed safety of eptifibatide combo but no added benefit.
  • Anticoagulation in AF: Earlier DOAC start (≤4d) is safe with no added bleeding risk — tailor to severity.
  • DVT/PE Prophylaxis: Delay pharmacologic prophylaxis ≥24h

1. Neurological Monitoring

Patients receiving tPA should undergo close monitoring in an ICU or step-down unit for the first 24 hours. This includes:

  • Neurologic checks (q15 min x 2h, q30 min x 6h, q1h until 24h)
  • BP monitoring and management
  • Emergent CT if neurological deterioration occurs

2. Blood Pressure Management

ENCHANTED Trial: Compared intensive BP lowering (SBP <140 mmHg) to guideline-based target (SBP <180 mmHg) after thrombolysis. Intensive strategy showed no difference in functional outcome.

Clinical Pearl: Target SBP <180 mmHg remains standard post-IVT, though intensive reduction is safe in selected patients.

3. Early Mobilization

AVERT Trial: Found that very early, frequent mobilization (<24h post-stroke) may worsen outcomes.

Additional Evidence: Several studies suggest that early mobilization between 12–24 hours post-tPA is generally safe, may shorten hospital stay, but has not been shown to significantly impact long-term functional outcomes.

Guideline Update: Delay mobilization for at least 12–24 hours post-tPA. Initiate rehab once medically stable and neurological status is assessed.

4. Antithrombotic and Anticoagulation Timing

Antiplatelets

  • Standard: Withhold aspirin or antiplatelets for 24 hours post-tPA
  • CLEAR Trial: Combined low-dose tPA + eptifibatide was safe but not superior

Anticoagulation for Atrial Fibrillation

ELAN Trial (2023): Early DOAC initiation (≤48h for minor, 3–6d for moderate) was non-inferior to delayed start, with similar ICH risk.

OPTIMAS Trial (2024): Confirmed that early initiation (≤4 days) of anticoagulation was non-inferior to delayed start (≥7 days) for prevention of recurrent ischemic stroke, with no increase in sICH.

Clinical Pearl: Both trials support earlier DOAC use in AF-related strokes, personalized by stroke severity and hemorrhagic risk.

5. DVT and PE Prophylaxis

  • IPC devices: Recommended for all non-ambulatory patients immediately
  • Pharmacologic prophylaxis: Delay ≥24h post-tPA; reassess hemorrhagic risk

6. Transition of Care & Secondary Prevention

  • Functional status and rehabilitation planning
  • Dysphagia screening before oral intake
  • Early secondary prevention (statins, BP meds, DOACs/antiplatelets)
  • Stroke education and outpatient follow-up

References

  1. Anderson CS, et al. ENCHANTED trial. N Engl J Med. 2019.
  2. Bernhardt J, et al. AVERT trial. N Engl J Med. 2015.
  3. Mouhayar E, et al. CLEAR trial. Stroke. 2011.
  4. Ferro JM, et al. ELAN trial. N Engl J Med. 2023;389:1386–1397.
  5. Hildick-Smith DJ, et al. OPTIMAS trial. Presented at ESOC 2024.